![]() |
市場調查報告書
商品編碼
1504207
臨床試驗的市場規模,佔有率,預測,趨勢分析:各類服務,各治療領域,不同階段,各終端用戶-2031年前的全球預測Clinical Trials Market Size, Share, Forecast, & Trends Analysis by Service Therapeutic Area Phase, End User - Global Forecast to 2031 |
到2031年,臨床試驗市場預計將達到1022億美元,2024年至2031年的複合年增長率為7.2%。
本報告在對市場情景進行廣泛的二次研究、初步研究和詳細分析後,對主要行業促進因素、市場限制因素、市場促進因素和課題進行了分析。臨床試驗市場的成長是由對罕見疾病的日益關注、個人化醫療的日益採用、研發成本的上升以及透過改進臨床試驗招募流程提高參與者保留率所推動的。然而,更長的臨床試驗持續時間、更嚴格的法規以及不斷變化的法律增加了臨床試驗的複雜性,正在限制該市場的成長。
此外,利用醫療物聯網 (IoMT)、基於雲端的藥物警戒系統以及將人工智慧整合到臨床試驗中的以患者為中心的臨床試驗的進展預計將為市場利益相關者提供成長機會。然而,缺乏熟練和專業的公司進行臨床試驗、臨床試驗方案的複雜性以及缺乏多種族的參與是臨床試驗市場的主要課題。我們還將數位健康技術引入臨床試驗,在臨床試驗中使用可穿戴技術、臨床試驗自動化、臨床試驗分散化、用於患者豐富和招募的AI建模和預測以及使用AI分析的臨床試驗等都是值得注意的。
(註:提供前 5 名公司 SWOT 分析)
Clinical Trials Market Size, Share, Forecast, & Trends Analysis by Service (Consulting, Patient Recruitment, Data Management, Regulatory, Site Support), Therapeutic Area (Oncology, Cardiology, Diabetes, Dermatology), Phase, End User-Global Forecast to 2031
The clinical trials market is projected to reach $102.20 billion by 2031, at a CAGR of 7.2% from 2024 to 2031.
After extensive secondary and primary research and an in-depth analysis of the market scenario, the report provides an analysis of key industry drivers, restraints, opportunities, and challenges. The growth of the clinical trials market is driven by the increasing focus on rare diseases, the rising adoption of personalized medicine, increasing research & development expenditures, and improvements in the clinical trials recruitment process resulting in improved participant retention. However, the extended durations of clinical trials, stringent regulations, and changing laws increasing the complexity of clinical trials restrain the growth of this market.
Furthermore, patient-centric clinical trials using the Internet of Medical Things (IoMT), advancements in cloud-based systems for pharmacovigilance, and the integration of AI into clinical trials are expected to offer growth opportunities for market stakeholders. However, the lack of skilled professionals to conduct clinical trials, the complexity of clinical trial protocols, and the lack of participation from several ethnic groups are major challenges in the clinical trials market. Also, the incorporation of digital health technologies into clinical trials, the use of wearable technologies for clinical trials, automation of clinical trials, decentralized clinical trials, AI modeling and forecasting of patient enrichment and recruitment, and AI-enabled clinical trial analytics are prominent trends in the clinical trials market.
The report offers a competitive landscape based on an extensive assessment of the leading players' product portfolios, geographic presence, and key strategies adopted over the last four years (2020-2024). The key players operating in the clinical trials market are Laboratory Corporation of America Holdings (U.S.), Medpace, Inc. (U.S.), Charles River Laboratories International, Inc. (U.S.), IQVIA Inc. (U.S.), Parexel International Corporation (U.S.), Syneos Health (U.S.), ICON plc (Ireland), WuXi AppTec Co., Ltd. (China), Thermo Fisher Scientific Inc. (U.S.), Fortrea Inc. (U.S.), Celerion Inc. (U.S.), Novotech Health Holdings (Australia), SGS Societe Generale de Surveillance SA. (Switzerland), CTI Clinical Trial and Consulting, Inc. (U.S.), and Linical USA, Inc. (U.S.).
Based on phase, the clinical trials market is segmented into pre-clinical trials, phase I, phase II, phase III, and phase IV. In 2024, the phase III segment is expected to account for the largest share of 68.4% of the clinical trials market. Phase III clinical trials use large groups of people to observe the adverse effects of treatments and utilize sophisticated services for studying the efficacy and safety of drugs. Such factors have contributed to the largest share of this segment. Additionally, many pharmaceutical and biotechnology companies outsource their phase III clinical trials to service providers, supporting the segment's large share.
Among all the therapeutic areas studied in this report, in 2024, the oncology segment is expected to account for the largest share of the clinical trials market. The largest share of this segment is attributed to the high prevalence of cancer, government support to develop new cancer medicines, high healthcare expenditure for cancer, and an increasing number of clinical trials in oncology. For instance, according to a November 2023 report by Pharmaceutical Research and Manufacturers of America (U.S.), 1,600 treatments and vaccines are in development for cancer. Such developments are expected to support the segment's large share.
Among all the end users studied in this report, in 2024, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the clinical trials market. The segment's large share is attributed to the increasing demand for innovative therapies for various diseases. Pharmaceutical & biotechnology companies' high investments in R&D for the development of new drugs and therapies are driving clinical trials, contributing to the segment's large share.
An in-depth analysis of the geographical scenario in the clinical trials market provides detailed qualitative and quantitative insights into five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2024, North America is expected to account for the largest share of 41.6% of the clinical trials market. North America's significant market share is attributed to increasing R&D investments, the rising adoption of new technologies in clinical trials, and the presence of key market players in this region. For instance, in March 2024, the Laboratory Corporation of America Holdings (U.S.) launched pTau217, a biomarker test for accelerating the diagnosis of Alzheimer's disease, which is also used for clinical trials. Additionally, according to the National Library of Medicine (U.S.), approximately 149,999 clinical trial studies were registered in the U.S. as of April 2024.
Clinical Trials Market Assessment-by Phase
Clinical Trials Market Assessment-by Service Type
Note: Other services include sample storage & aliquoting services, laboratory services, research review services, manufacturing services, cold chain logistics & management services, and In-Country Clinical Caretaker (ICCC) Services.
Clinical Trials Market Assessment-by Therapeutic Area
Clinical Trials Market Assessment-by End User
Note: Other end users include Contract Research Organizations (CROs), academic & research institutions, and government organizations.
Clinical Trials Market Assessment-by Geography
(Note: SWOT analyses of the top 5 companies will be provided.)